Equities Analysts Issue Forecasts for INSP FY2025 Earnings

Inspire Medical Systems, Inc. (NYSE:INSP) – Stock analysts at KeyCorp lifted their FY2025 earnings per share (EPS) estimates for Inspire Medical Systems in a report issued on Sunday, January 25th. KeyCorp analyst B. Fishbin now forecasts that the company will post earnings of $1.63 per share for the year, up from their prior estimate of $1.57. KeyCorp currently has a “Sector Weight” rating on the stock. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share. KeyCorp also issued estimates for Inspire Medical Systems’ Q4 2025 earnings at $0.70 EPS and FY2026 earnings at $1.81 EPS.

Other equities research analysts have also recently issued reports about the stock. UBS Group set a $96.00 price objective on shares of Inspire Medical Systems in a research note on Thursday, January 22nd. JPMorgan Chase & Co. raised their target price on shares of Inspire Medical Systems from $82.00 to $118.00 and gave the company a “neutral” rating in a research note on Tuesday, December 16th. Oppenheimer lowered shares of Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 22nd. Royal Bank Of Canada cut shares of Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $175.00 to $90.00 in a report on Tuesday. Finally, Robert W. Baird raised their price objective on shares of Inspire Medical Systems from $125.00 to $180.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $133.47.

Inspire Medical Systems Stock Performance

NYSE:INSP opened at $78.65 on Wednesday. Inspire Medical Systems has a 1 year low of $70.77 and a 1 year high of $203.12. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of 53.50, a PEG ratio of 8.27 and a beta of 0.72. The business has a fifty day moving average of $105.84 and a 200-day moving average of $95.65.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.53. The business had revenue of $224.50 million during the quarter, compared to analyst estimates of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 EPS.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds have recently modified their holdings of INSP. Farther Finance Advisors LLC boosted its position in shares of Inspire Medical Systems by 14.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 603 shares of the company’s stock valued at $78,000 after purchasing an additional 77 shares during the period. New York State Teachers Retirement System lifted its stake in Inspire Medical Systems by 0.5% during the second quarter. New York State Teachers Retirement System now owns 21,490 shares of the company’s stock valued at $2,789,000 after buying an additional 100 shares in the last quarter. Xponance Inc. lifted its stake in Inspire Medical Systems by 2.9% during the third quarter. Xponance Inc. now owns 4,177 shares of the company’s stock valued at $310,000 after buying an additional 116 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Inspire Medical Systems by 1.3% in the second quarter. Amalgamated Bank now owns 9,567 shares of the company’s stock worth $1,242,000 after buying an additional 125 shares during the period. Finally, Daiwa Securities Group Inc. increased its position in shares of Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 130 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares of the company’s stock, valued at $3,320,344.08. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.10% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.